Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2024

Screening and Diagnosing of Ph+ ALL in Adults

The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.

Episodes in this series

EP. 1 Overview of Characteristics Unique to Ph+ ALL

EP. 1 Overview of Characteristics Unique to Ph+ ALL

EP. 2 Timely Detection: Incidence and Prevalence of Ph+ ALL

EP. 2 Timely Detection: Incidence and Prevalence of Ph+ ALL

EP. 3 Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP. 3 Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

Video 4 - "Screening and Diagnosing of Ph+ ALL in Adults"

EP. 4 Screening and Diagnosing of Ph+ ALL in Adults

Video 5 - "Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management"

EP. 5 Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

Video 6 - "Current Front-Line Targeted Treatments in Ph+ ALL"

EP. 6 Current Front-Line Targeted Treatments in Ph+ ALL

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 7 Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 8 PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"

EP. 9 Value-Based Care Models Optimizing Ph+ ALL Patient Care

VIdeo 10 - "Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL"

EP. 10 Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

Video 11 - "Disparities in Access to Care for Ph+ ALL patients"

EP. 11 Disparities in Access to Care for Ph+ ALL patients

Video 12 - "The Future of Ph+ ALL Treatments"

EP. 12 The Future of Ph+ ALL Treatments

Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"

EP. 13 Concluding Thoughts on Ph+ ALL Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Anita Kumar, MD, of MSKCC in Basking Ridge, New Jersey, highlighted advances in treatment of transplant-ineligible mantle cell lymphoma, including chemotherapy-free options. | Image: MSKCC

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

June 20th 2026

Myeloproliferativedisorder | Image Credit: © ibreakstock-stock.adobe.com

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

ByMaggie L. Shaw

June 19th 2026

Principal investigator Sara A. Hurvitz, MD, said results with the gedatolisib combinations show they could be the new standard of care in HR+/HER2- advanced breast cancer. | Image: Fred Hutch

In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer

June 19th 2026

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Trial Eligibility Requirements Capture Only a Fraction of Adults With Sickle Cell Disease: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 19th 2026

Fibrosis Belongs at Center of MASH End Points: Zobair M. Younossi, MD

ByLaura Joszt, MA,Zobair M. Younossi, MD

June 19th 2026

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Defunding Co-Payment Assistance Disrupted nAMD Care

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer